Pharmacokinetics, pharmacodynamics and safety of CKD-519, a CETP inhibitor, in healthy subjects

Choon Ok Kim1 Department of Clinical Pharmacology, Severance Hospital, Yonsei University College of Medicine, Seoul

Eun Sil Oh2 Department of Pharmaceutical Medicines and Regulatory Science, Colleges of Medicine and Pharmacy, Yonsei University, Incheon

Chungam Choi1 Department of Clinical Pharmacology, Severance Hospital, Yonsei University College of Medicine, Seoul

Yeonjoo Kim3 Chong Kun Dang Clinical Research, Chong Kun Dang Pharmaceutical Corp.

Sera Lee4 Chong Kun Dang Research Institute, Chong Kun Dang Pharmaceutical Corp.

Semi Kim4 Chong Kun Dang Research Institute, Chong Kun Dang Pharmaceutical Corp.

Min Soo Park1 Department of Clinical Pharmacology, Severance Hospital, Yonsei University College of Medicine, Seoul;5 Department of Pediatrics, Yonsei University College of Medicine, Seoul, Republic of KoreaCorrespondence[email protected]

show all

Pages 3763-3770 | Published online: 15 Nov 2016

Cite this article
CrossMark

Full Article
Figures & data
References
Citations
Metrics
Licensing
Reprints & Permissions
View PDF PDF

References

OhiraTIsoHCardiovascular disease epidemiology in Asia: an overviewCirc J20137771646165223803294
PubMed Web of Science ®Google Scholar
Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in AdultsExecutive summary of the third report of the National Cholesterol Education Program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III)JAMA2001285192486249711368702
PubMed Web of Science ®Google Scholar
GrundySMCleemanJIMerzCNImplications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelinesCirculation2004110222723915249516
PubMed Web of Science ®Google Scholar
BaigentCKeechAKearneyPMEfficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statinsLancet200536694931267127816214597
PubMed Web of Science ®Google Scholar
BarterPGottoAMLaRosaJCHDL cholesterol, very low levels of LDL cholesterol, and cardiovascular eventsN Engl J Med2007357131301131017898099
PubMed Web of Science ®Google Scholar
SharrettARBallantyneCMCoadySACoronary heart disease prediction from lipoprotein cholesterol levels, triglycerides, lipoprotein(a), apolipoproteins A-I and B, and HDL density subfractions: the Atherosclerosis Risk in Communities (ARIC) StudyCirculation2001104101108111311535564
PubMed Web of Science ®Google Scholar
JafriHAlsheikh-AliAAKarasRHMeta-analysis: statin therapy does not alter the association between low levels of high-density lipoprotein cholesterol and increased cardiovascular riskAnn Intern Med20101531280080821173414
PubMed Web of Science ®Google Scholar
GordonTCastelliWPHjortlandMCKannelWBDawberTRHigh density lipoprotein as a protective factor against coronary heart disease. The Framingham StudyAm J Med1977625707714193398
PubMed Web of Science ®Google Scholar
KontushAGuérinMChapmanMJSpotlight on HDL-raising therapies: insights from the torcetrapib trialsNat Clin Pract Cardiovasc Med20085632933618431367
PubMedGoogle Scholar
DullensSPPlatJMensinkRPIncreasing apoA-I production as a target for CHD risk reductionNutr Metab Cardiovasc Dis200717861662817703927
PubMed Web of Science ®Google Scholar
BarterPKasteleinJNunnAHobbsRFuture Forum Editorial Board. High density lipoproteins (HDLs) and atherosclerosis; the unanswered questionsAtherosclerosis2003168219521112801602
PubMed Web of Science ®Google Scholar
ClarkRWSutfinTARuggeriRBRaising high-density lipoprotein in humans through inhibition of cholesteryl ester transfer protein: an initial multidose study of torcetrapibArterioscler Thromb Vasc Biol200424349049714739125
PubMed Web of Science ®Google Scholar
de GroothGJKuivenhovenJAStalenhoefAFEfficacy and safety of a novel cholesteryl ester transfer protein inhibitor, JTT-705, in humans: a randomized phase II dose-response studyCirculation2002105182159216511994249
PubMed Web of Science ®Google Scholar
TallARPlasma cholesteryl ester transfer proteinJ Lipid Res1993348125512748409761
PubMed Web of Science ®Google Scholar
MiyaresMAAnacetrapib and dalcetrapib: two novel cholesteryl ester transfer protein inhibitorsAnn Pharmacother2011451849421205945
PubMed Web of Science ®Google Scholar
BarterPJCaulfieldMErikssonMEffects of torcetrapib in patients at high risk for coronary eventsN Engl J Med2007357212109212217984165
PubMed Web of Science ®Google Scholar
ForrestMJBloomfieldDBriscoeRJTorcetrapib-induced blood pressure elevation is independent of CETP inhibition and is accompanied by increased circulating levels of aldosteroneBr J Pharmacol200815471465147318536749
PubMed Web of Science ®Google Scholar
SchwartzGGOlssonAGAbtMEffects of dalcetrapib in patients with a recent acute coronary syndromeN Engl J Med2012367222089209923126252
PubMed Web of Science ®Google Scholar
ZhaoHPDaiYXiangBRDiscontinued cardiovascular drugs in 2015Expert Opin Investig Drugs201625910931101
PubMed Web of Science ®Google Scholar
McLainJHAlsterdaAJAroraRRCholesteryl ester transfer protein inhibitors: trials and tribulationsJ Cardiovasc Pharmacol Ther2016 pii:1074248416662349
PubMed Web of Science ®Google Scholar
LeeSAbstract 11228: a novel and potent CETP inhibitor, CKD-519 exerts strong HDL increment and anti-atherosclerotic effectsCirculation2013128Suppl 22A11228
Web of Science ®Google Scholar
SmithBPVandenhendeFRDeSanteKAConfidence interval criteria for assessment of dose proportionalityPharm Res200017101278128311145235
PubMed Web of Science ®Google Scholar
MartinGPilonAAlbertCComparison of expression and regulation of the high-density lipoprotein receptor SR-BI and the low-density lipoprotein receptor in human adrenocortical carcinoma NCI-H295 cellsEur J Biochem1999261248149110215860
PubMedGoogle Scholar

Share icon
Back to Top

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.

People also read
Recommended articles
Cited by

To cite this article:

Reference style: APA Chicago Harvard

Citation copied to clipboard

Reference styles above use APA (6th edition), Chicago (16th edition) & Harvard (10th edition)

Download citation

Download a citation file in RIS format that can be imported by citation management software including EndNote, ProCite, RefWorks and Reference Manager.

Choose format: RIS BibTex RefWorks Direct Export

Choose options: Citation Citation & abstract Citation & references

Pharmacokinetics, pharmacodynamics and safety of CKD-519, a CETP inhibitor, in healthy subjects

References

Information for

Open access

Opportunities

Help and information

Your download is now in progress and you may close this window

Login or register to access this feature

Pharmacokinetics, pharmacodynamics and safety of CKD-519, a CETP inhibitor, in healthy subjects

References

Related research

To cite this article:

Download citation

Information for

Open access

Opportunities

Help and information

Keep up to date